Opendata, web and dolomites

DMD2CURE

Correction of duplications in the DMD gene by a CRISPR/Cas9 approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DMD2CURE project word cloud

Explore the words cloud of the DMD2CURE project. It provides you a very rough idea of what is the project "DMD2CURE" about.

tools    contiguous    disorder    date    represented    skipping    incidence    regions    live    duplication    termination    strategy    generally    grna    deletions    applicable    inversion    exist    uses    premature    tandem    mutations    alterations    pave    sequence    leiden    births    arena    duchenne    duplications    exonic    dystrophy    cardiac    milestones    recessive       induce    pathologies    technologies    occurs    chose    repair    removing    therapy    coding    synthetic    sequences    revolutionizing    gene    premises    cas9    protein    translation    restoring    reported    frame    almost    limited    exon    genome    followed    employ    wasting    skeletal    shift    motor    10    500    sites    identical    delayed    fibrosis    disease    crispr    despite    model    nucleases    dmd    muscle    deletion    editing    treatment    linked    database    muscular    molecular    progressive    feasible    diseases    promises    necrosis    dystrophin    therapies    hold    therapeutic    frequent    deleted       mutation    introduce    respiratory    weakening    intronic    expression    male   

Project "DMD2CURE" data sheet

The following table provides information about the project.

Coordinator
ASSOCIATION GENETHON 

Organization address
address: RUE DE L INTERNATIONALE 1 BIS
city: EVRY
postcode: 91002
website: www.genethon.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.genethon.fr/en/
 Total cost 185˙076 €
 EC max contribution 185˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIATION GENETHON FR (EVRY) coordinator 185˙076.00

Map

 Project objective

Duchenne muscular dystrophy is an X-linked recessive muscle-wasting disease, characterized by progressive weakening of skeletal, respiratory, and cardiac muscle followed by necrosis and fibrosis. DMD affects ~1:3,500 live male births and is associated with delayed motor milestones. DMD occurs as a result of mutations within the DMD gene that lead to premature termination of translation. The most frequent type of mutations are exonic deletions and duplications that induce a frame-shift in the protein-coding sequence. To date no effective treatment exist for this disorder. Duplications account for ~5–10% of all reported mutations in DMD in the Leiden database, although the incidence may be higher. Despite the limited number in DMD, duplications are widespread in almost all diseases and are generally neglected by therapeutic approaches. New molecular tools, now represented by genome-editing technologies that use synthetic nucleases in order to introduce targeted alterations at specific sites in the genome, hold great promises for revolutionizing the gene therapy arena. According to these premises, we propose a novel strategy based on the CRISPR/Cas9 system to repair tandem duplications by removing the mutation: compared to the exon deletions approach which uses two gRNA targeting two unique regions defining the sequence to be deleted, our approach will employ only one gRNA against a unique intronic sequence within the tandem duplication. This strategy will exploit the characteristic of tandem duplication (two identical contiguous sequences) and will result in the deletion or inversion of the mutation restoring the dystrophin expression. As a model we chose the exon 2 duplication which is the most frequent one in the DMD gene, but the same approach would be applicable to all tandem duplications. This study will pave the way for the development of therapies against duplications also in pathologies in which the exon skipping approach is not feasible.

 Publications

year authors and title journal last update
List of publications.
2017 Annalisa Lattanzi, Stephanie Duguez, Arianna Moiani, Araksya Izmiryan, Elena Barbon, Samia Martin, Kamel Mamchaoui, Vincent Mouly, Francesco Bernardi, Fulvio Mavilio, Matteo Bovolenta
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
published pages: 11-19, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.02.004
Molecular Therapy - Nucleic Acids 7 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DMD2CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DMD2CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

GLORIOUS (2019)

Digital Poetry in Today’s Russia: Canonisation and Translation

Read More  

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More